Evidence map›Paper›PMID 41145282›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Identify the factors associated with treatment-free remission outcomes after imatinib discontinuation in children and adolescent patients with chronic myeloid leukemia].

H F Zhao, Q Jiang, W M Li, Y Zhu, B C Liu, Q S Zeng, S X Guo, L X Liang, C L Zhang, Y L Zu and 2 more

Abstract readMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

H F ZhaoAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
Q JiangPeople's Hospital of Peking University, Peking University Institute of Hematology, National Clinical Medical Research Center for Blood System Diseases, Beijing 100044, China.
W M LiUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 436022, China.
Y ZhuThe First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, China.
B C LiuInstitute of Hematology and Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hematology, Tianjin 300020, China.
Q S ZengThe First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
S X GuoZhengzhou People's Hospital, Zhengzhou 450003, China.
L X LiangSanmenxia Central Hospital, Sanmenxia 472000, China.
C L ZhangAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
Y L ZuAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
Y P SongAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
Yanli ZhangAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Imatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentChildChild, PreschoolFemaleHumansMaleProportional Hazards ModelsRemission InductionRetrospective StudiesTreatment OutcomeYoung AdultImatinib MesylateChildren and adolescentImatinibLeukemia, myeloid, chronicTreatment-free remission

Identifiers

PMID41145282
PMCPMC12580795

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.